New endpoints in adrenocortical carcinoma studies: a mini review.
Adrenocortical carcinoma
Endpoints
PRO
QOL
Surrogate
Journal
Endocrine
ISSN: 1559-0100
Titre abrégé: Endocrine
Pays: United States
ID NLM: 9434444
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
received:
28
04
2022
accepted:
25
06
2022
pubmed:
24
7
2022
medline:
20
8
2022
entrez:
23
7
2022
Statut:
ppublish
Résumé
Adrenocortical carcinoma (ACC) is a very rare and aggressive malignant disease. Therefore, overall survival (OS) has long been considered as the best endpoint. Yet, a unique endpoint is not optimal to take into account the heterogeneity in tumor profile and the diversification of therapeutic option. The purpose of this mini review was to describe endpoints used in the past, present and future in the field of ACC. Pubmed and Clinicaltrial.gov were used to identify relevant studies. Before year 2000 only three endpoints were regularly used: OS, recurrence-free survival (RFS) and response rate. These endpoints were used because ACC was seen as a homogeneous diseases with a high recurrence rate and low rate of long-term survival. Since 2000; along with the apparition of new class of drug, progression-free survival (PFS) has been more and more used. Other endpoints as "time to chemotherapy" or "Progression-free survival 2" were used to evaluate multimodal therapies or treatment with a delayed action. Finally, there is a hope that in the near future, quality of life along with other patient-reported outcomes may be used more frequently. While OS and PFS are currently the most used endpoints in ACC, new endpoints are needed to better take into account the challenges offered by different situations and treatment strategies.
Identifiants
pubmed: 35869971
doi: 10.1007/s12020-022-03128-2
pii: 10.1007/s12020-022-03128-2
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
419-424Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and Other Tools) Resource (Food and Drug Administration (US), Silver Spring (MD), 2016)
T. Burzykowski, G. Molenberghs, M. Buyse, H. Geys, D. Renard, Validation of surrogate end points in multiple randomized clinical trials with failure time end points. J. R. Stat. Soc.: Ser. C. (Appl. Stat.) 50, 405–422 (2001). https://doi.org/10.1111/1467-9876.00244
doi: 10.1111/1467-9876.00244
M. Buyse, G. Molenberghs, T. Burzykowski, D. Renard, H. Geys, The validation of surrogate endpoints in meta-analyses of randomized experiments. Biostatistics 1, 49–67 (2000). https://doi.org/10.1093/biostatistics/1.1.49
doi: 10.1093/biostatistics/1.1.49
pubmed: 12933525
M. Fassnacht, M. Terzolo, B. Allolio, E. Baudin, H. Haak, A. Berruti et al. Combination chemotherapy in advanced adrenocortical carcinoma. N. Engl. J. Med. 366, 2189–2197 (2012). https://doi.org/10.1056/NEJMoa1200966
doi: 10.1056/NEJMoa1200966
pubmed: 22551107
M. Terzolo, M. Fassnacht, P. Perotti, R. Libe, A. Lacroix, D. Kastelan et al. Results of the ADIUVO study, the first randomized trial on adjuvant mitotane in adrenocortical carcinoma patients. J. Endocr. Soc. 5, A166–A167 (2021). https://doi.org/10.1210/jendso/bvab048.336
doi: 10.1210/jendso/bvab048.336
pmcid: 8265733
M. Fassnacht, A. Berruti, E. Baudin, M.J. Demeure, J. Gilbert, H. Haak et al. Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. Lancet Oncol. 16, 426–435 (2015). https://doi.org/10.1016/S1470-2045(15)70081-1
doi: 10.1016/S1470-2045(15)70081-1
pubmed: 25795408
J.J.H. Park, E. Siden, M.J. Zoratti, L. Dron, O. Harari, J. Singer et al. Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols. Trials 20, 572 (2019). https://doi.org/10.1186/s13063-019-3664-1
doi: 10.1186/s13063-019-3664-1
pubmed: 31533793
pmcid: 6751792
P. Icard, P. Goudet, C. Charpenay, B. Andreassian, B. Carnaille, Y. Chapuis et al. Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. World J. Surg. 25, 891–897 (2001). https://doi.org/10.1007/s00268-001-0047-y
doi: 10.1007/s00268-001-0047-y
pubmed: 11572030
R. Libé, I. Borget, C.L. Ronchi, B. Zaggia, M. Kroiss, T. Kerkhofs et al. Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study. Ann. Oncol. 26, 2119–2125 (2015). https://doi.org/10.1093/annonc/mdv329
doi: 10.1093/annonc/mdv329
pubmed: 26392430
Y.S. Elhassan, B. Altieri, S. Berhane, D. Cosentini, A. Calabrese, M. Haissaguerre et al. S-GRAS score for prognostic classification of adrenocortical carcinoma: an international, multicenter ENSAT study. Eur. J. Endocrinol. 186, 25–36 (2021). https://doi.org/10.1530/EJE-21-0510
doi: 10.1530/EJE-21-0510
pubmed: 34709200
pmcid: 8679848
L.M. Weiss, L.J. Medeiros, A.L. Vickery, Pathologic features of prognostic significance in adrenocortical carcinoma. Am. J. Surg. Pathol. 13, 202–206 (1989). https://doi.org/10.1097/00000478-198903000-00004
doi: 10.1097/00000478-198903000-00004
pubmed: 2919718
A. de Reyniès, G. Assié, D.S. Rickman, F. Tissier, L. Groussin, F. René-Corail et al. Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. J. Clin. Oncol. 27, 1108–1115 (2009). https://doi.org/10.1200/JCO.2008.18.5678
doi: 10.1200/JCO.2008.18.5678
pubmed: 19139432
E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, R. Ford et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228–247 (2009). https://doi.org/10.1016/j.ejca.2008.10.026
doi: 10.1016/j.ejca.2008.10.026
pubmed: 19097774
R. Ambrosini, M.C. Balli, M. Laganà, M. Bertuletti, L. Bottoni, F. Vaccher et al. Adrenocortical carcinoma and CT assessment of therapy response: the value of combining multiple criteria. Cancers 12, E1395 (2020). https://doi.org/10.3390/cancers12061395
doi: 10.3390/cancers12061395
pubmed: 32481732
A. Berruti, M. Terzolo, P. Sperone, A. Pia, S. Della Casa, D.J. Gross et al. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocr. Relat. Cancer 12, 657–666 (2005). https://doi.org/10.1677/erc.1.01025
doi: 10.1677/erc.1.01025
pubmed: 16172198
M. Laganà, S. Grisanti, D. Cosentini, V.D. Ferrari, B. Lazzari, R. Ambrosini et al. Efficacy of the EDP-M scheme plus adjunctive surgery in the management of patients with advanced adrenocortical carcinoma: the Brescia experience. Cancers 12, E941 (2020). https://doi.org/10.3390/cancers12040941
doi: 10.3390/cancers12040941
pubmed: 32290298
P. Malandrino, A. Al Ghuzlan, M. Castaing, J. Young, B. Caillou, J.-P. Travagli et al. Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma. Endocr. Relat. Cancer 17, 797–807 (2010). https://doi.org/10.1677/ERC-09-0341
doi: 10.1677/ERC-09-0341
pubmed: 20592067
M. Fassnacht, S. Johanssen, M. Quinkler, P. Bucsky, H.S. Willenberg, F. Beuschlein et al. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. Cancer 115, 243–250 (2009). https://doi.org/10.1002/cncr.24030
doi: 10.1002/cncr.24030
pubmed: 19025987
N. Raj, Y. Zheng, V. Kelly, S.S. Katz, J. Chou, R.K.G. Do et al. PD-1 blockade in advanced adrenocortical carcinoma. J. Clin. Oncol. 38, 71–80 (2020). https://doi.org/10.1200/JCO.19.01586
doi: 10.1200/JCO.19.01586
pubmed: 31644329
A. Berruti, V. Amoroso, F. Gallo, V. Bertaglia, E. Simoncini, R. Pedersini et al. Pathologic complete response as a potential surrogate for the clinical outcome in patients with breast cancer after neoadjuvant therapy: a meta-regression of 29 randomized prospective studies. J. Clin. Oncol. 32, 3883–3891 (2014). https://doi.org/10.1200/JCO.2014.55.2836
doi: 10.1200/JCO.2014.55.2836
pubmed: 25349292
A.M. Lerario, F.P. Worden, C.A. Ramm, E.A. Hesseltine, E.A. Hasseltine, W.M. Stadler et al. The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial. Horm. Cancer 5, 232–239 (2014). https://doi.org/10.1007/s12672-014-0182-1
doi: 10.1007/s12672-014-0182-1
pubmed: 24849545
pmcid: 4298824
M. Kroiss, M. Quinkler, S. Johanssen, N.P. van Erp, N. Lankheet, A. Pöllinger et al. Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial. J. Clin. Endocrinol. Metab. 97, 3495–3503 (2012). https://doi.org/10.1210/jc.2012-1419
doi: 10.1210/jc.2012-1419
pubmed: 22837187
A. Berruti, P. Sperone, A. Ferrero, A. Germano, A. Ardito, A.M. Priola et al. Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma. Eur. J. Endocrinol. 166, 451–458 (2012). https://doi.org/10.1530/EJE-11-0918
doi: 10.1530/EJE-11-0918
pubmed: 22189997
M.A. Habra, B. Stephen, M. Campbell, K. Hess, C. Tapia, M. Xu et al. Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma. J. Immunother. Cancer 7, 253 (2019). https://doi.org/10.1186/s40425-019-0722-x
doi: 10.1186/s40425-019-0722-x
pubmed: 31533818
pmcid: 6751592
C. O’Sullivan, M. Edgerly, M. Velarde, J. Wilkerson, A.M. Venkatesan, S. Pittaluga et al. The VEGF inhibitor axitinib has limited effectiveness as a therapy for adrenocortical cancer. J. Clin. Endocrinol. Metab. 99, 1291–1297 (2014). https://doi.org/10.1210/jc.2013-2298
doi: 10.1210/jc.2013-2298
pubmed: 24423320
pmcid: 3973787
B.A. Carneiro, B. Konda, R.B. Costa, R.L.B. Costa, V. Sagar, D.B. Gursel et al. Nivolumab in metastatic adrenocortical carcinoma: results of a phase 2 trial. J. Clin. Endocrinol. Metab. 104, 6193–6200 (2019). https://doi.org/10.1210/jc.2019-00600
doi: 10.1210/jc.2019-00600
pubmed: 31276163
I.G. Hermsen, M. Fassnacht, M. Terzolo, S. Houterman, J. den Hartigh, S. Leboulleux et al. Plasma concentrations of o,p’DDD, o,p’DDA, and o,p’DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study. J. Clin. Endocrinol. Metab. 96, 1844–1851 (2011). https://doi.org/10.1210/jc.2010-2676
doi: 10.1210/jc.2010-2676
pubmed: 21470991
F. Megerle, W. Herrmann, W. Schloetelburg, C.L. Ronchi, A. Pulzer, M. Quinkler et al. Mitotane monotherapy in patients with advanced adrenocortical carcinoma. J. Clin. Endocrinol. Metab. 103, 1686–1695 (2018). https://doi.org/10.1210/jc.2017-02591
doi: 10.1210/jc.2017-02591
pubmed: 29452402
D.L. Reidy-Lagunes, B. Lung, B.R. Untch, N. Raj, A. Hrabovsky, C. Kelly et al. Complete responses to mitotane in metastatic adrenocortical carcinoma—a new look at an old drug. Oncologist 22, 1102–1106 (2017). https://doi.org/10.1634/theoncologist.2016-0459
doi: 10.1634/theoncologist.2016-0459
pubmed: 28559412
pmcid: 5599197
D. Vezzosi, C. Do Cao, S. Hescot, J. Bertherat, M. Haissaguerre, V. Bongard et al. Time until partial response in metastatic adrenocortical carcinoma long-term survivors. Horm. Cancer 9, 62–69 (2018). https://doi.org/10.1007/s12672-017-0313-6
doi: 10.1007/s12672-017-0313-6
pubmed: 29071575
S. Hescot, S. Leboulleux, C. Caramella, A. Paci, M. Lombes, A. Berdelou et al. Early progression under mitotane and polychemotherapy does not mean failure in adrenocortical carcinoma patient. Ann. Endocrinol. 78, 67–69 (2017). https://doi.org/10.1016/j.ando.2016.10.001
doi: 10.1016/j.ando.2016.10.001
A. Boilève, E. Mathy, C. Roux, M. Faron, J. Hadoux, L. Tselikas et al. Combination of mitotane and locoregional treatments in low-volume metastatic adrenocortical carcinoma. J. Clin. Endocrinol. Metab. 106, e4698–e4707 (2021). https://doi.org/10.1210/clinem/dgab449
doi: 10.1210/clinem/dgab449
pubmed: 34143888
J.-Y. Blay, C. Honoré, E. Stoeckle, P. Meeus, M. Jafari, F. Gouin et al. Surgery in reference centers improves survival of sarcoma patients: a nationwide study. Ann. Oncol. 30, 1407 (2019). https://doi.org/10.1093/annonc/mdz170
doi: 10.1093/annonc/mdz170
pubmed: 31168580
pmcid: 6683855
R.V. Steenaard, L.A. Michon, H.R. Haak, Health-related quality of life in adrenocortical carcinoma. Cancers 11, E1500 (2019). https://doi.org/10.3390/cancers11101500
doi: 10.3390/cancers11101500
pubmed: 31597261
R. Schwarz, A. Hinz, Reference data for the quality of life questionnaire EORTC QLQ-C30 in the general German population. Eur. J. Cancer 37, 1345–1351 (2001). https://doi.org/10.1016/s0959-8049(00)00447-0
doi: 10.1016/s0959-8049(00)00447-0
pubmed: 11435063
M. Milian, P. Teufel, J. Honegger, B. Gallwitz, G. Schnauder, T. Psaras, The development of the Tuebingen Cushing’s disease quality of life inventory (Tuebingen CD-25). Part I: construction and psychometric properties. Clin. Endocrinol. 76, 851–860 (2012). https://doi.org/10.1111/j.1365-2265.2011.04191.x
doi: 10.1111/j.1365-2265.2011.04191.x
S.M. Webb, X. Badia, M.J. Barahona, A. Colao, C.J. Strasburger, A. Tabarin et al. Evaluation of health-related quality of life in patients with Cushing’s syndrome with a new questionnaire. Eur. J. Endocrinol. 158, 623–630 (2008). https://doi.org/10.1530/EJE-07-0762
doi: 10.1530/EJE-07-0762
pubmed: 18426820